Syntis Bio Appoints Matthew Dallas as Chief Financial Officer
Syntis Bio, a clinical-stage biopharmaceutical company developing oral therapeutics designed to leverage the small intestine, has appointed Matthew Dallas as... Read More
The post Syntis Bio Appoints Matthew Dallas as Chief Financial Officer appeared first on citybiz.